CLDN18 and gastric cancer: Currently, the most accredited modality for identifying CLDN18 positive vs. negative cases in gastric cancer is based on calculating the percentage of 2 +/3 + positive tumor cells, considering positive those cases with ≥ 75% of 2 +/3 + cells [23].